» Articles » PMID: 27757418

Promiscuous Targeting of Bromodomains by Bromosporine Identifies BET Proteins As Master Regulators of Primary Transcription Response in Leukemia

Abstract

Bromodomains (BRDs) have emerged as compelling targets for cancer therapy. The development of selective and potent BET (bromo and extra-terminal) inhibitors and their significant activity in diverse tumor models have rapidly translated into clinical studies and have motivated drug development efforts targeting non-BET BRDs. However, the complex multidomain/subunit architecture of BRD protein complexes complicates predictions of the consequences of their pharmacological targeting. To address this issue, we developed a promiscuous BRD inhibitor [bromosporine (BSP)] that broadly targets BRDs (including BETs) with nanomolar affinity, creating a tool for the identification of cellular processes and diseases where BRDs have a regulatory function. As a proof of principle, we studied the effects of BSP on leukemic cell lines known to be sensitive to BET inhibition and found, as expected, strong antiproliferative activity. Comparison of the modulation of transcriptional profiles by BSP after a short exposure to the inhibitor resulted in a BET inhibitor signature but no significant additional changes in transcription that could account for inhibition of other BRDs. Thus, nonselective targeting of BRDs identified BETs, but not other BRDs, as master regulators of context-dependent primary transcription response.

Citing Articles

Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application.

Chen Y, Liang R, Li Y, Jiang L, Ma D, Luo Q Signal Transduct Target Ther. 2024; 9(1):340.

PMID: 39627201 PMC: 11615378. DOI: 10.1038/s41392-024-02030-9.


Identification of Novel Bromodomain-Containing Protein 4 (BRD4) Binders through 3D Pharmacophore-Based Repositioning Screening Campaign.

Colarusso E, Gazzillo E, Boccia E, Terracciano S, Bruno I, Bifulco G Molecules. 2024; 29(17).

PMID: 39274873 PMC: 11397543. DOI: 10.3390/molecules29174025.


Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic strategy for progranulin-deficient frontotemporal dementia.

Rosenthal Z, Fass D, Payne N, She A, Patnaik D, Hennig K Sci Rep. 2024; 14(1):9064.

PMID: 38643236 PMC: 11032351. DOI: 10.1038/s41598-024-59110-7.


Identification and Development of BRD9 Chemical Probes.

Colarusso E, Chini M, Bifulco G, Lauro G, Giordano A Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543178 PMC: 10976250. DOI: 10.3390/ph17030392.


An iron rheostat controls hematopoietic stem cell fate.

Kao Y, Chen J, Kumari R, Ng A, Zintiridou A, Tatiparthy M Cell Stem Cell. 2024; 31(3):378-397.e12.

PMID: 38402617 PMC: 10939794. DOI: 10.1016/j.stem.2024.01.011.


References
1.
Vidler L, Brown N, Knapp S, Hoelder S . Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J Med Chem. 2012; 55(17):7346-59. PMC: 3441041. DOI: 10.1021/jm300346w. View

2.
Clark P, Vieira L, Tallant C, Fedorov O, Singleton D, Rogers C . LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. Angew Chem Int Ed Engl. 2015; 54(21):6217-21. PMC: 4449114. DOI: 10.1002/anie.201501394. View

3.
Kadoch C, Hargreaves D, Hodges C, Elias L, Ho L, Ranish J . Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013; 45(6):592-601. PMC: 3667980. DOI: 10.1038/ng.2628. View

4.
Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

5.
Miller J, Cai C, Langfelder P, Geschwind D, Kurian S, Salomon D . Strategies for aggregating gene expression data: the collapseRows R function. BMC Bioinformatics. 2011; 12:322. PMC: 3166942. DOI: 10.1186/1471-2105-12-322. View